REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) Director Kenneth T. Mills sold 12,221 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $13.78, for a total transaction of $168,405.38. Following the completion of the sale, the director now owns 408,035 shares in the company, valued at $5,622,722.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
REGENXBIO Price Performance
Shares of REGENXBIO stock traded down $0.06 on Friday, reaching $14.33. 318,287 shares of the company were exchanged, compared to its average volume of 638,509. REGENXBIO Inc. has a 1-year low of $10.49 and a 1-year high of $28.80. The company has a market cap of $705.90 million, a P/E ratio of -2.44 and a beta of 1.26. The stock’s 50 day moving average price is $13.07 and its 200-day moving average price is $16.04.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.10). REGENXBIO had a negative return on equity of 70.72% and a negative net margin of 299.96%. The company had revenue of $15.60 million for the quarter, compared to analyst estimates of $23.52 million. During the same period in the prior year, the firm posted ($1.53) earnings per share. The business’s quarterly revenue was down 18.3% compared to the same quarter last year. On average, research analysts predict that REGENXBIO Inc. will post -4.37 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Report on RGNX
Institutional Investors Weigh In On REGENXBIO
Several large investors have recently modified their holdings of RGNX. Redmile Group LLC raised its stake in shares of REGENXBIO by 21.0% during the first quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock worth $95,901,000 after purchasing an additional 790,866 shares during the last quarter. Assenagon Asset Management S.A. raised its position in REGENXBIO by 258.7% in the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock worth $9,552,000 after acquiring an additional 588,773 shares in the last quarter. Vanguard Group Inc. raised its position in REGENXBIO by 9.8% in the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after acquiring an additional 436,043 shares in the last quarter. Perceptive Advisors LLC purchased a new position in REGENXBIO in the fourth quarter worth $6,146,000. Finally, Artal Group S.A. purchased a new position in REGENXBIO in the first quarter worth $5,268,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
- Five stocks we like better than REGENXBIO
- 3 Monster Growth Stocks to Buy Now
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- The 3 Best Fintech Stocks to Buy Now
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Investing In Preferred Stock vs. Common Stock
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.